SpeedWeed

MAY 22, 2021

After years of delays, legal challenges, and obfuscation, the US Drug Enforcement Agency (DEA) finally announced that it would begin evaluating applications for federally-licensed research cannabis cultivators. . In 2019, a federal judge forced the DEA to explain its inaction.

DEA 52

DEA Cultivation Research and Development Cannabis 52

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The recommendation for rescheduling cannabis marked the first time a government agency officially recognized cannabis’ medical benefits.

Research and Development 62

Research and Development DEA Chronic Pain Business 62

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 66

DEA Clinical Trials THC Research and Development 66

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Veriheal

NOVEMBER 6, 2023

states and the District of Columbia currently have legal cannabis, medical or recreational. Despite this massive shift in cannabis policy, however, a few states are still dragging their feet on cannabis legalization. Idaho Idaho is one of the staunchest anti-cannabis states. Like Idaho, CBD with less than.3%

Legalization 117

Legalization Recreational THC CBD 117

Cannabis Law Report

NOVEMBER 17, 2022

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp.

Research and Development 52

Research and Development Pharmaceutical DEA Cannabinoids 52

United Patients Group

APRIL 3, 2023

Introduction A cannabis ‘prescription’ is written by a doctor to be dispensed at a pharmacy (i.e. A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal.

DEA 52

DEA Patients Conditions Cannabis 52

Cannabis Law Report

JANUARY 22, 2020

It also directs the Commission to research “important current issues facing law enforcement and the criminal justice system,” and recommends a variety of subjects for study, such as, but not limited to” There is no direct mention of cannabis but a senior DEA appointment we would suggest is a message in itself. WASHINGTON, D.C.

DEA 69

DEA Law Research and Development Strains 69

Cannabis Law Report

AUGUST 17, 2022

Among other things, the bill would ease limitations on medical research on cannabis and cannabidiol (CBD). Drug Enforcement Administration (DEA) to register practitioners to conduct cannabis and CBD research and manufacturers to supply cannabis for research purposes. Specifically, the bill would: Direct the U.S.

CBD 52

CBD DEA Research and Development Epilepsy 52

The Blunt Truth

DECEMBER 15, 2023

The Department of Health and Human Services released documents related to rescheduling cannabis. The DEA sends a letter to Georgia pharmacies. And finally, if you’re planning a wedding, you have a cannabis option. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it.

DEA 59

DEA Legislation Legalization Consumption 59

The Joint Blog

JUNE 4, 2021

The United States Food and Drug Administration (FDA) has only cannabis use to treat two rare and severe forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous. Cachexia or wasting syndrome.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Veriheal

NOVEMBER 11, 2023

Many states in the US have legalized cannabis, thirty-eight states to be exact. Despite the widespread adoption, the Food and Drug Administration still classifies cannabis as a Schedule One drug. Simply put, in the eyes of federal law, cannabis is illegal. Is Medical Cannabis Legal? allow the use of medical cannabis.

Law 62

Law Chronic Pain Conditions Legislation 62

Medical Marijuana Program Connection

MAY 5, 2024

Drug Enforcement Administration’s (DEA) decision to reclassify marijuana as a positive step, despite the long road ahead.Late last week, the U.S. A Kansas City marijuana manufacturer sees the U.S. Read More

DEA 40

DEA Marijuana Cultivation Conditions 40

Canna Law Blog

JUNE 13, 2023

Drug Enforcement Administration (DEA) to implement and enforce the relevant provisions of the Controlled Substances Import and Export Act which makes it a crime to bring controlled substances into the country without a proper license. CBP coordinates with a wide range of partner government agencies (e.g., FDA, EPA, DOT, ATF, CPSC, etc.)

DEA 63

DEA Marijuana Hemp Concentrates 63

Veriheal

SEPTEMBER 13, 2022

The legal cannabis industry in the United States has slowly expanded over the last decade. Despite the federal illegality of cannabis, lawmakers and state representatives have implemented successful medical and recreational cannabis programs across the nation. Homegrown Cannabis Statistics: Supplies, Growers and Products .

Cultivation 109

Cultivation Data DEA Dispensary 109

Canna Law Blog

AUGUST 16, 2022

If you’re a cannabis lab, researcher, or scientist, the NIH is interested in hearing your thoughts! Last week, the National Institute of Health (NIH) posted a request for information (RFI)* regarding identifying the barriers to cannabis research. What barriers prevent cannabis research?

DEA 66

DEA Access Cannabinoids Cannabis 66

Cannabis Law Report

SEPTEMBER 12, 2022

Government Agencies seek funding to research cannabinoids as treatments for various conditions: [link]. Florida Ag Commissioner blasts Biden administration for arguing in lawsuit that medical cannabis patients “are too dangerous to trust” to possess firearms: [link]. Louisiana allows doctors to decide conditions: [link].

DEA 98

DEA Dispensary Hemp Therapy 98

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules were developed in accordance with the state’s new law on medical cannabis, which was approved earlier this year by the state Legislature and signed into law by the governor.

Patients 52

Patients DEA Dispensary Conditions 52

Canna Law Blog

NOVEMBER 6, 2021

The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). But federal lawsuits on cannabis rescheduling provide guidance and suggest that FDA approval is not a requirement for meeting that criterion.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Blunt Truth

MAY 20, 2021

Alabama, moving in the opposite direction, legalized medical cannabis. The DEA moved forward on cannabis research (really!). Approved by the voters in November 2020, it died this week in the state’s Supreme Court, where the justices declared that it was based on conditions that no longer exist. mississippi.

Decriminalization 106

Decriminalization DEA CBD Marijuana 106

Canna Law Blog

JULY 2, 2022

On June 14, 2022, Harris Bricken attorneys Fred Rocafort, Jihee Ahn, Paul Coble, and Vincent Silwoski presented a webinar entitled Protecting, Monetizing and Enforcing Cannabis Intellectual Property. In this post, we will answer the cannabis patent questions that were not addressed in the webinar. delta-9-THC).

Extraction 69

Extraction Strains Conditions Cannabis 69

FloridaMarijuana.net

JULY 8, 2018

5 cannabis strains to treat PTSD? When the body is defensive against trauma or illness, this system begins to fail, resulting in physical, mental and/or neurological conditions. Cannabis offers significant therapeutic benefits for a wide range of medical conditions. 5 cannabis strains to treat PTSD: 1.

Strains 190

Strains Indica Hybrid Research and Development 190

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Nature's Way Medicine

FEBRUARY 12, 2021

In this week’s news and updates, we have updates about how Ohio’s medical marijuana market is doing, political lobyists in the cannabis industry, and the Senate’s push for legalization. Senate Majority Leader Chuck Schumer Spearheads Effort to Legalize Cannabis. Federal News. State News.

Research and Development 97

Research and Development Patients CBD DEA 97

Veriheal

JUNE 23, 2022

The legalization of cannabis is opening many doors in states that are embracing it. The lack of effective tools to measure cannabis impairment accurately, in practice, encourages the criminalization of legal cannabis in states where a legal grey area exists. Current Testing for Cannabis Impairment Is Not Precise.

Consumption 104

Consumption Legalization Concentrates Patients 104

Cannabis Law Report

JULY 23, 2021

On Wednesday, July 14, 2021 Senators Chuck Schumer (D-NY), Cory Booker (D-NJ), and Ron Wyden (D-OR) released draft legislation titled the Cannabis Administration and Opportunity Act. If implemented, regulatory responsibility of cannabis would be transferred from the U.S. Draft Bill Details.

Research and Development 105

Research and Development DEA Programs State Laws 105

Cannabis Law Report

JANUARY 23, 2020

Cannabis Catalysts write by way of an introduction. “After taking the first steps towards the liberalization of hemp cultivation over the course of the last few years, at the end of 2018 Thailand’s government decided to legalize medical cannabis as the first Southeast Asian country. CC INSIGHTS THAILAND MEDICAL CANNABIS.

Research and Development 59

Research and Development Oil Cultivation DEA 59

Veriheal

AUGUST 19, 2022

For several decades now, hemp, psilocybin, and cannabis products, in general, have been frowned upon by the federal government. But times are changing, and leaders are now calling for revamped policies on psilocybin, hemp, and cannabis research for varying reasons. ” Cannabis Research Should Be Based on Real, Accessible Products.

Hemp 52

Hemp DEA Access Cultivation 52

Cannabis Law Report

JULY 7, 2019

RE-PUBLISHED BY : CANNABIS LAW REPORT. Notwithstanding, this re-branding and imaging of cannabis, the basis for much of this confusion is the Controlled Substances Act. As a refresher, cannabis is classified as a “Schedule I” substance, which, defines it as a substance with no currently accepted medical use. De Ingeniis.

DEA 40

DEA Pharmaceutical Conditions Patients 40

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug. Conclusion.

Therapy 52

Therapy Patients Law Clinical Trials 52

Canna Law Blog

NOVEMBER 21, 2021

Cannabis is legal and regulated in most U.S. It’s entirely plausible that they go the route of cannabis (as is happening in Oregon) or some new route (as is happening with local grassroots decrim efforts). In all likelihood, FDA-approved MDMA would be prescribed and administered in very similar conditions.

Decriminalization 84

Decriminalization DEA Conditions Food 84

Veriheal

MAY 4, 2022

If you search the term “cannabis and heart health” on Google, you’ll notice that the results are flooded with pages upon pages of claims about the plant’s allegedly negative impacts on cardiovascular health. Is the cannabis plant a true culprit for poor heart health ? But just how true are these claims?

Research and Development 98

Research and Development Consumption Vaping Edibles 98

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA). Times (Nov.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

DECEMBER 1, 2020

Cannabis was labeled with a stigma and stereotype that is very difficult to break. Years of negative propaganda at the hands of the US federal government has painted a picture of cannabis consumers being lazy, unmotivated individuals having no motivation, drive, or desire to be good contributing members of society.

THC 52

THC DEA Research and Development Cannabinoids 52